351 related articles for article (PubMed ID: 37001909)
1. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
2. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon AC; Burton LB; Chwalisz BK; Hillis J; Schaller TH; Amato AA; Betof Warner A; Brastianos PK; Cho TA; Clardy SL; Cohen JV; Dietrich J; Dougan M; Doughty CT; Dubey D; Gelfand JM; Guptill JT; Johnson DB; Juel VC; Kadish R; Kolb N; LeBoeuf NR; Linnoila J; Mammen AL; Martinez-Lage M; Mooradian MJ; Naidoo J; Neilan TG; Reardon DA; Rubin KM; Santomasso BD; Sullivan RJ; Wang N; Woodman K; Zubiri L; Louv WC; Reynolds KL
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281989
[TBL] [Abstract][Full Text] [Related]
3. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST; Semenov YR; Alloo A; Bach DQ; Betof Warner A; Bougrine A; Burton L; Cappelli LC; Castells M; Cohen J; Dewan AK; Fadden R; Guggina L; Hegde A; Huang V; Johnson DB; Kaffenberger B; Kroshinsky D; Kwatra S; Kwong B; Lacouture ME; Larocca C; Leventhal J; Markova A; McDunn J; Mooradian MJ; Naidoo J; Choi J; Nambudiri V; Nelson CA; Patel AB; Pimkina J; Rine J; Rubin KM; Sauder M; Shaigany S; Shariff A; Sullivan RJ; Zubiri L; Reynolds KL; LeBoeuf NR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599660
[TBL] [Abstract][Full Text] [Related]
4. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
8. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
9. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
10. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
[TBL] [Abstract][Full Text] [Related]
11. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
Nashed A; Zhang S; Chiang CW; Zitu M; Otterson GA; Presley CJ; Kendra K; Patel SH; Johns A; Li M; Grogan M; Lopez G; Owen DH; Li L
Cancer Immunol Immunother; 2021 Oct; 70(10):2761-2769. PubMed ID: 33625533
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
16. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
18. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]